Procter & Gamble donates proprietary "super aspirin" technology to Vanderbilt University

November 01, 2000

NASHVILLE, TN (November 2, 2000) - The next "super aspirin" may be among a collection of 196 patents and pending patents given today to Vanderbilt University by Cincinnati-based Procter & Gamble (NYSE: PG). P&G's proprietary COX-2 Inhibitor Technology shows promise in improving the safety of medications commonly taken for pain, inflammation, and fever reduction.

Along with the patents, P&G is donating all associated intellectual property. As the sole new owners of the technology, Vanderbilt will benefit from all future revenues after the technology is further developed, tested, and commercialized.

"We are pleased that Vanderbilt's international reputation in the area of eicosanoids (COX products) has been affirmed by this generous gift of intellectual property, and we are excited with the opportunity to develop it into something of clinical value," said Lee E. Limbird, Ph.D., associate vice chancellor for Research.

Procter & Gamble's external consultants identified Vanderbilt as the university that is most uniquely qualified to further develop the COX-2 Inhibitor Technology due to their on-going leadership in COX-2 research. In addition, Vanderbilt's Office of Enterprise Development gives the framework for commercializing the technology.

"We're excited that Vanderbilt will continue to develop and test this significant technology, and that Vanderbilt will benefit both financially and academically from this donation," said P&G's Chief Technology Officer Gil Cloyd. "Best of all, we'll get to see this promising science furthered to improve peoples' lives - even if it will no longer be in P&G hands."

The gift of COX-2 Inhibitor Technology is the sixth in a series of Procter & Gamble technology donations to leading universities and research institutions.

About COX-2 inhibitor technology

COX-2 Inhibitor Technology compounds block the action of an enzyme called cyclooxygenase-2 (COX-2), and like other recently marketed COX-2 inhibitors, they could relieve pain and inflammation without the gastric side effects of other non-steroidal anti-inflammatory drugs (NSAIDs). What is different about P&G's COX-2 Inhibitor Technology is that it may also promote ulcer healing and even prevent the development of NSAID-induced ulcers, a relatively common side effect of the drugs.

Examples of NSAIDs currently available over-the-counter are Motrin, Aleve and Advil; prescriptions include Celebrex (Searle/Pfizer) and Vioxx (Merck).

"Currently marketed prescription NSAIDs slow the healing of ulcers that are already present. We'll be researching just how P&G's COX-2 Inhibitor Technology is working to promote - versus delay -- ulcer healing," said Dr. L. Jackson Roberts II, professor of Pharmacology and Medicine.

To develop the Procter & Gamble compound as a therapeutic drug, Vanderbilt established a new company called PharmaVU, Inc. through the Office of Enterprise Development with an investment from the University's Chancellor Fund. PharmaVU plans to contract the remaining pre-clinical toxicology studies to an outside company and then to conduct Phase I clinical trials.

"Carrying the drug through Phase I trials will greatly enhance its value," Roberts said. "At that point it should be very attractive for a company to license and further develop it through Phase II and Phase III trials and eventually marketing."

The global market for COX-2 inhibitor drugs is approximately three billion dollars annually, and the global market for all analgesics, including COX-2 inhibitors, is expected to reach $12 billion by 2003. Vanderbilt University's future revenues of this technology could reach $1 billion per year.

Promising Future in Alzheimer's, Cancer

The particular COX-2 Inhibitor Technology being given today also shows potential in the prevention and treatment of cancer and Alzheimer's disease - areas that Vanderbilt researchers will continue to investigate.

"There is great excitement about the potential of COX-2 inhibitors for both cancer prevention and cancer treatment," said Dr. Mace L. Rothenberg, Ingram Professor of Cancer Research, associate professor of Medicine, and director of Phase I Drug Development for the Vanderbilt-Ingram Cancer Center.

"In addition, COX-2 inhibitors can be combined with chemotherapy and thereby potentiate the anti-tumor activity of the chemotherapy," Rothenberg said. "We will conduct pre-clinical screening of a large number of drug combinations, including the P&G COX-2 Inhibitor Technology compounds, to help identify leads for cancer treatment."

In addition to cancer research, Vanderbilt intends to research COX-2 Inhibitor Technology's potential for Alzheimer's Disease. Initial research on COX-2 inhibitors indicates that they may reduce the risk of Alzheimer's or delay its onset.

About Vanderbilt University

Vanderbilt University is a private research university of approximately 5,900 undergraduates and 4,300 graduate and professional students. Founded in 1873, the University comprises 10 schools, a public policy institute, a distinguished medical center and The Freedom Forum First Amendment Center. Vanderbilt offers undergraduate programs in the liberal arts and sciences, education and human development, engineering and music, and a full range of graduate and professional degrees.

For more news about Vanderbilt, visit the Media Relations homepage at www.vanderbilt.edu/news.

About Procter & Gamble

P&G markets 300 brands to nearly five billion consumers in 140 countries. P&G invests nearly $2 billion a year to develop and improve its products -- leading the way in R&D globally among consumer products companies. P&G's Global Licensing Organization is promoting the full development and use of the company's innovations. This includes selling, licensing and, in select cases, donating P&G's technologies.
-end-


Vanderbilt University Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.